Views & Analysis Who will be the biggest pharma players in orphan drugs? New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Roche coming out in the lead.
News After epilepsy setback, Zogenix buys Modis and rare disease ... Zogenix has bounced back from the FDA’s rejection of its only drug, with the acquisition of Modis Therapeutics and a developmental rare disease drug that has already been championed by regu
News Daiichi Sankyo’s pexidartinib is first FDA-approved drug for... /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0;
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.